Peroxisome proliferator-activated receptor-γ activation with angiotensin ii type 1 receptor blockade is pivotal for the prevention of blood-brain barrier impairment and cognitive decline in type 2 diabetic mice

Hypertension

Volumn 59, Issue 5, 2012, Pages 1079-1088

  Min, Li Juan ^a   Mogi, Masaki ^a   Shudou, Masachika ^b   Jing, Fei ^a   Tsukuda, Kana ^a   Ohshima, Kousei ^a   Iwanami, Jun ^a   Horiuchi, Masatsugu ^a  

^a EHIME UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b EHIME UNIVERSITY   (Japan)

Author keywords

Activation; AT 1 receptor blockade; Blood brain barrier; Cognitive decline; Diabetes; PPAR ; Swollen astrocytic end feet

Indexed keywords

2 CHLORO 5 NITROBENZANILIDE; ANGIOTENSIN 1 RECEPTOR; INTERLEUKIN 6; LOSARTAN; MATRIX METALLOPROTEINASE; MONOCYTE CHEMOTACTIC PROTEIN 1; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; TELMISARTAN; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ATTENUATION; BLOOD BRAIN BARRIER; BRAIN CORTEX; COGNITION; COGNITIVE DEFECT; CONTROLLED STUDY; CYTOKINE PRODUCTION; ENZYME ACTIVATION; HIPPOCAMPUS; INFLAMMATION; MACROGLIA; MALE; MEMBRANE PERMEABILITY; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; SWELLING; TIGHT JUNCTION;

ANALYSIS OF VARIANCE; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANILIDES; ANIMALS; BENZIMIDAZOLES; BENZOATES; BLOOD GLUCOSE; BLOOD-BRAIN BARRIER; BLOTTING, WESTERN; COGNITION DISORDERS; DIABETES MELLITUS, EXPERIMENTAL; DIABETES MELLITUS, TYPE 2; DISEASE MODELS, ANIMAL; LOSARTAN; MALE; MAZE LEARNING; MICE; MICE, INBRED C57BL; PPAR GAMMA; RANDOM ALLOCATION; SENSITIVITY AND SPECIFICITY;

EID: 84860224428     PISSN: 0194911X     EISSN: 15244563     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.112.192401     Document Type: Article

References (40)

1. Ballabh P, Braun A, Nedergaard M. The blood-brain barrier: an overview-structure, regulation, and clinical implications. Neurobiol Dis. 2004;16:1-13. (Pubitemid 38569790)
2. Taheri S, Gasparovic C, Huisa BN, Adair JC, Edmonds E, Prestopnik J, Grossetete M, Shah NJ, Wills J, Qualls C, Rosenberg GA. Blood-brain barrier permeability abnormalities in vascular cognitive impairment. Stroke. 2011;42:2158-2163.
3. Yang Y, Rosenberg GA. MMP-mediated disruption of claudin-5 in the blood-brain barrier of rat brain after cerebral ischemia. Methods Mol Biol. 2011;762:333-345.
4. Jeynes B, Provias J. The case for blood-brain barrier dysfunction in the pathogenesis of Alzheimer's disease. J Neurosci Res. 2011;89:22-28.
5. Petty MA, Lo EH. Junctional complexes of the blood-brain barrier: permeability changes in neuroinflammation. Prog Neurobiol. 2002;68:311-323. (Pubitemid 36071509)
6. Biessels GJ, Deary IJ, Ryan CM. Cognition and diabetes: a lifespan perspective. Lancet Neurol. 2008;2:184-190.
7. Yi SS, Hwang IK, Kim DW, Shin JH, Nam SM, Choi JH, Lee CH, Won MH, Seong JK, Yoon YS. The chronological characteristics of SOD1 activity and inflammatory response in the hippocampi of STZ-induced type1 diabetic rats. Neurochem Res. 2011;36:117-128.
8. Kamada H, Yu F, Nito C, Chan PH. Influence of hyperglycemia on oxidative stress and matrix metalloproteinase-9 activation after cerebral ischemia/reperfusion in rats: relation to blood-brain barrier dysfunction. Stroke. 2007;38:1044-1049. (Pubitemid 46568472)
9. Starr JM, Wardlaw J, Ferguson K, MacLullich A, Deary IJ, Marshall I. Increased blood-brain barrier permeability in type II diabetes demonstrated by gadolinium magnetic resonance imaging. J Neurol Neurosurg Psychiatry. 2003;74:70-76. (Pubitemid 36069039)
10. Hawkins BT, Lundeen TF, Norwood KM, Brooks HL, Egleton RD. Increased blood-brain barrier permeability and altered tight junctions in experimental diabetes in the rat: contribution of hyperglycaemia and matrix metalloproteinases. Diabetologia. 2007;50:202-211. (Pubitemid 46035869)
11. Schrader J, Luders S, Kulschewski A, Berger J, Zidek W, Treib J, Einhaupl K, Diener HC, Dominiak P. The ACCESS Study: evaluation of Acute Candesartan Cilexetil Therapy in Stroke Survivors. Stroke. 2003;34:1699-1703. (Pubitemid 36842630)
12. Li NC, Lee A, Whitmer RA, Kivipelto M, Lawler E, Kazis LE, Wolozin B. Use of angiotensin receptor blockers and risk of dementia in a predominantly male population: prospective cohort analysis. BMJ. 2010;340:b5465.
13. Tsukuda K, Mogi M, Li JM, Iwanami J, Min LJ, Sakata A, Fujita T, Iwai M, Horiuchi M. Amelioration of cognitive impairment in the type-2 diabetic mouse by the angiotensin II type-1 receptor blocker candesartan. Hypertension. 2007;50:1099-1105. (Pubitemid 350172932)
14. Kurtz TW, Klein U. Next generation multifunctional angiotensin receptor blockers. Hypertens Res. 2009;32:826-834.
15. Benson SC, Pershadsingh HA, Ho CI, Chittiboyina A, Desai P, Pravenec M, Qi N, Wang J, Avery MA, Kurtz TW. Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARγ-modulating activity. Hypertension. 2004;43:993-1002. (Pubitemid 38579904)
16. Schupp M, Janke J, Clasen R, Unger T, Kintscher U. Angiotensin type 1 receptor blockers induce peroxisome proliferator-activated receptor-activity. Circulation. 2004;109:2054-2057. (Pubitemid 38620211)
17. Tsukuda K, Mogi M, Iwanami J, Min LJ, Sakata A, Jing F, Iwai M, Horiuchi M. Cognitive deficit in amyloid-γ-injected mice was improved by pretreatment with a low dose of telmisartan partly because of peroxisome proliferator-activated receptor-activation. Hypertension. 2009;54:782-787.
18. Kamal A, Biessels GJ, Duis SE, Gispen WH. Learning and hippocampal synaptic plasticity in streptozotocin-diabetic rats: interaction of diabetes and ageing. Diabetologia. 2000;43:500-506. (Pubitemid 30237960)
19. Kalayci R, Kaya M, Ahishali B, Arican N, Elmas I, Kucuk M. Long-term L-NAME treatment potentiates the blood-brain barrier disruption during pentylenetetrazole-induced seizures in rats. Life Sci. 2006;79:16-20. (Pubitemid 44255531)
20. Armulik A, Genove G, Mae M, Nisancioglu MH, Wallgard E, Niaudet C, He L, Norlin J, Lindblom P, Strittmatter K, Johansson BR, Betsholtz C. Pericytes regulate the blood-brain barrier. Nature. 2010;468:557-561.
21. Min LJ, Mogi M, Li JM, Iwanami J, Iwai M, Horiuchi M. Aldosterone and angiotensin II synergistically induce mitogenic response in vascular smooth muscle cells. Circ Res. 2005;97:434-442. (Pubitemid 41298173)
22. Qin L, He J, Hanes RN, Pluzarev O, Hong JS, Crews FT. Increased systemic and brain cytokine production and neuroinflammation by endotoxin following ethanol treatment. J Neuroinflamm. 2008;5:10.
23. Szocs K, Lasseque B, Sorescu D, Hilenski LL, Valppu L, Couse TL, Wilcox JN, Quinn MT, Lambeth JD, Griendling KK. Upregulation of Nox-based NAD(P)H oxidases in restenosis after carotid injury. Arterioscler Thromb Vasc Biol. 2002;22:21-27. (Pubitemid 34076227)
24. Fleegal-DeMotta MA, Doghu S, Banks WA. Angiotensin II modulates BBB permeability via activation of the AT(1) receptor in brain endothelial cells. J Cereb Blood Flow Metab. 2009;29:640-647.
25. Pelisch N, Hosomi N, Ueno M, Nakano D, Hitomi H, Mogi M, Shimada K, Kobori H, Horiuchi M, Sakamoto H, Matsumoto M, Kohno M, Nishiyama A. Blockade of AT1 receptors protects the blood-brain barrier and improves cognition in dahl salt-sensitive hypertensive rats. Am J Hypertens. 2011;24:362-368.
26. Horiuchi M, Mogi M. Role of angiotensin II receptor subtype activation in cognitive function and ischaemic brain damage. Br J Pharmacol. 2011;163:1122-1130.
27. Morishita R, Kanda Y, Nakajima M. Irbesartan: second generation of ARB as metabosartan. Curr Hypertens Rev. 2010;6:173-179.
28. Mott JD, Werb Z. Regulation of matrix biology by matrix metalloproteinases. Curr Opin Cell Biol. 2004;16:558-564. (Pubitemid 39201241)
29. Kadoglou NP, Daskalopoulou SS, Perrea D, Liapis CD. Matrix metalloproteinases and diabetic vascular complications. Angiology. 2005;56:173-189. (Pubitemid 40404472)
30. Derosa G, Avanzini MA, Geroldi D, Fogari R, Lorini R, De Silvestri A, Tinelli C, d'Annunzio G. Matrix metalloproteinases 2 may be a marker of microangiopathy in children and adolescents with type 1 diabetes mellitus. Diabetes Res Clin Pract. 2005;70:119-125.
31. Signorelli SS, Malaponte G, Libra M, Di Pino L, Celotta G, Bevelacqua V, Petrina M, Nicotra GS, Indelicato M, Navolanic PM, Pennisi G, Mazzarino MC. Plasma levels and zymographic activities of matrix metalloproteinases 2 and 9 in type II diabetics with peripheral arterial disease. Vasc Med. 2005;10:1-6. (Pubitemid 40667579)
32. Navaratna D, McGuire PG, Menicucci G, Das A. Proteolytic degradation of VE-cadherin alters the blood-retinal barrier in diabetes. Diabetes. 2007;56:2380-2387. (Pubitemid 47358245)
33. Marioni RE, Strachan MW, Reynolds RM, Lowe GD, Mitchell RJ, Fowkes FG, Frier BM, Lee AJ, Butcher I, Rumley A, Murray GD, Deary IJ, Price JF. Association between raised inflammatory markers and cognitive decline in elderly people with type 2 diabetes: the Edinburgh Type 2 Diabetes Study. Diabetes. 2010;59:710-713.
34. Tham DM, Martin-McNulty B, Wang YX, Wilson DW, Vergona R, Sullivan ME, Dole W, Rutledge JC. Angiotensin II is associated with activation of NF-kappaB-mediated genes and downregulation of PPARs. Physiol Genomics. 2002;11:21-30. (Pubitemid 37128718)
35. Sugawara A, Takeuchi K, Uruno A, Ikeda Y, Arima S, Kudo M, Sato K, Taniyama Y, Ito S. Transcriptional suppression of type 1 angiotensin II receptor gene expression by peroxisome proliferator-activated receptor-in vascular smooth muscle cells. Endocrinology. 2001;142:3125-3134. (Pubitemid 32575551)
36. Rizzo G, Fiorucci S. PPARs and other nuclear receptors in inflammation. Curr Opin Pharmacol. 2006;6:421-427.
37. Washida K, Ihara M, Nishio K, Fujita Y, Maki T, Yamada M, Takahashi J, Wu X, Kihara T, Ito H, Tomimoto H, Takahashi R. Nonhypotensive dose of telmisartan attenuates cognitive impairment partially due to peroxisome proliferator-activated receptor-activation in mice with chronic cerebral hypoperfusion. Stroke. 2010;41:1798-1806.
38. Haorah J, Ramirez SH, Schall K, Smith D, Pandya R, Persidsky Y. Oxidative stress activates protein tyrosine kinase and matrix metalloproteinases leading to blood-brain barrier dysfunction. J Neurochem. 2007;101:566-576. (Pubitemid 46525283)
39. Takata F, Dohgu S, Matsumoto J, Takahashi H, Machida T, Wakigawa T, Harada E, Miyaji H, Koga M, Nishioku T, Yamauchi A, Kataoka Y. Brain pericytes among cells constituting the blood-brain barrier are highly sensitive to tumor necrosis factor-, releasing matrix metalloproteinase-9 and migrating in vitro. J Neuroinflamm. 2011;8:106.
40. Biessels GJ, Staekenborg S, Brunner E, Brayne C, Scheltens P. Risk of dementia in diabetes mellitus: a systematic review. Lancet Neurol. 2006; 5:64-74. (Pubitemid 41790697)